|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Practice Parameters for the Treatment of Perianal Abscess and Fistula-in-Ano ?(Revised)显示文摘 | Mark H. Whiteford M.D. John Kilkenny M.D. Neil Hyman M.D. W. Donald Buie M.D. Jeffrey Cohen M.D. Charles Orsay M.D. Gary Dunn M.D. W. Brian Perry M.D. C. Neal Ellis M.D. Jan Rakinic M.D. Sharon Gregorcyk M.D. Paul Shellito M.D. Richard Nelson M.D. Joe J. | 2005 | Diseases of the Colon & Rectum2005，，7： | 2 |
| 2 | Protecting the delivery of heart failure: Regenerative Medicine/Stem Cell Therapeutics:Potential protections afforded by the Department of Health and Human Services and Health Resources Service Administration’s Bureau of Special Programs显示文摘Advances in stem cell science and potential clinical applications have brought clinical medicine closer to the actualization of Regenerative Medicine—an extension of transplantation of organs and cells and implantation of bioprosthetics and biodevices. The goal of such therapeutics will be intervention prior to onset of severe individual disability, enhance organ function and enhance patient performance status without incurring the economic impacts of standard organ transplantation. Regenerative Medicine is already demonstrating proof of principle or efficacy in restora- tion of myocardial contractility, joint mobility and function, immune competence, pulmonary function, immunologic self- tolerance, motor function and normal hemoglobin production with the next targets—diabetes mellitus (type I and type II), neurologic injury, hepatic dysfunction preparing to enter trials. Expenditures on health care needs of an aging U.S. citizenry approximate 20-25% ($3 trillion) of U.S. GDP currently and may to grow to 40% of U.S. GDP by 2025. As the potential of Regenerative Medicine is clinically realized, the societal impact and economic benefits will be disproportionately magnified in the economies of industrialized nations. The experi- ence of the Department of Health and Human Services (HHS), United Network for Organ Sharing (UNOS), the National Bone Marrow Donor Registry (NBMDR), and the National Vaccine Injury Compensation Programs (NVICP) can help ensure that as Regenerative Medicine strives to achieve clinical benefits while avoiding decimation of therapeutic options by product liability and medical malpractice concerns—concerns that crippled the U.S. vaccine manufacturing industry until the creation of the NVICP. The first 50 years of organ/cell/tissue transplantation demonstrates that clinical reality of allogeneic and autologous transplantation can antedate complete understanding of the basic science underlying successful transplantation. Product liability and medical malpractice liability have not impeded the development and growth of organ/cell/tissue transplanta- tion despite increased risks of infection, malignancy and cardiovascular disease in transplant recipients. Currently, human transplantation is only performed using FDA/CBER-approved, non-embryonic stem cells from peripheral blood, bone marrow or umbilical cord blood. Federal legislation passed in 2005 (HR2520 and S1317: The Bone Marrow and Cord Blood Cell Transplantation Program) authorizes the Secretary of Health and Human Services acting through the Director of HRSA to ensure uniform stem cell units distribution and outcomes monitoring via the federally-designated C.W. Bill Young Cell Transplant Program. Historically in the U.S., human biological therapies (vaccines, organ transplant and stem cell transplant) have re- quired federal protections to ensure continued distribution, fair access and avoidance of inhibitory product liability via protections afforded under the “stewardship” of the Secretary of Health and Human Services. The National Childhood Vaccine Injury Act of 1986 established the NVICP to equitably and expeditiously compensate individuals, or families of individuals, who have been declared injured by vaccines, thereby stabilizing a once imperiled vaccine supply by substan-tially reducing the threat of liability for vaccine companies, physicians, and other health care professionals who administer vaccines. Vaccines were the first biologics administered to U.S. citizens en masse and presage stem cell therapeutics (which may similarly be administered to millions) will similarly necessitate that a Stem Cell Injury Compensation Program (SCICP) will also need to be in place to demonstrate an intention to do good, an understanding that industry may do well, but that the health care consumer has a right of protection—all recognized from the outset. The Federal Tort Claims Act (FTCA) addresses liability claims via the Executive, Judicial and Legislative branches of Government, providing an um- brella of liability protection to other participants in the stem cell unit “chain of custody” under the FTCA—similar to the protection from product liability seen in organ and stem cell transplantation for the past 40-50 years. Efficacious development of regenerative medicine capabilities will mandate controlled access must first be provided for individuals with life-threatening diseases without therapeutic options or unable to benefit from or receive proven therapeutic options (ALS, cardiomyopathy and deemed not a candidate for heart transplantation, IDDM with hypoglyce- mic unawareness and no allogeneic source of traditional islet cell replacement available via HRSA) and mandates the prompt adoption of business and legal principles to ensure that the fate of the vaccine manufacturing industry does not become the fate of the stem cell therapeutics industry. If legal and regulatory concerns consume an increasing percentage of health care dollars that could be focused upon innovation, the Regenerative Medicine model will have not realized its full potential. The Diabetes Transplantation/Regenerative Medicine Model is the first organ to cell transplant model outside of oncology to demonstrate the regenerative medicine paradigm. Since all human tissues can be already recapitulated by human stem cells and key patent holders already exist, outlet or distribution of “more-than-minimally-manipulated stem cell units” as an IND approved under FDA/CBER guidelines can be accomplished via the current HHS/HRSA/Dept of Trans- plant methodology. As cardiovascular stem cell researchers develop human therapeutics utilizing more-than-minimally- manipulated stem cell products, they could be afforded protections from product liability historically enjoyed by the transplant community. Extending the Diabetes Transplant/Regenerative Medicine Model to the more than 5 million Americans with chronic heart failure, cell-based therapies to regenerate myocardial contractility could fill an existing void and be delivered in conjunction with and consistent with existing distribution of organs and tissues via HRSA/Department of Transplantation. | Gary S Friedman John S. Tomicki Neil Cohen Robert Marshal Philip Lowry Jeffrey Warsh | 2006 | Journal of Geriatric Cardiology2006，3，3： | 2 |
| 3 | Resource utiliza-tion, cost, and health status impacts of coronary stentversus 'optimal' percutaneous coronary angioplasty: re-sults from the OPUS-1 trial显示文摘 | Neil N Ramsey S D Cohen D J | 2002 | J Interv Cardiol2002，15，4： | 1 |
| 4 | Practice Parameters for the Management of Hemorrhoids (Revised)显示文摘 | Peter Cataldo M.D. C. Neal Ellis M.D. Sharon Gregorcyk M.D. Neil Hyman M.D. W. Donald Buie M.D. James Church M.D. Jeffrey Cohen M.D. Phillip Fleshner M.D. John Kilkenny M.D. Clifford Ko M.D. David Levien M.D. Richard Nelson M.D. Graham Newstead M.D. Charl | 2005 | Diseases of the Colon & Rectum2005，，2： | 1 |
| 5 | Practice Parameters for Colon Cancer显示文摘 | Daniel Otchy Neil H. Hyman Clifford Simmang Thomas Anthony Donald W. Buie Peter Cataldo James Church Jeffrey Cohen Frederick Dentsman Neal C. Ellis John W. Kilkenny Clifford Ko Richard Moore Charles Orsay Ronald Place Janice Rafferty Jan Rakinic Paul Savo | 2004 | Diseases of the Colon & Rectum2004，，： | 1 |
| 6 | Practice Parameters for the Treatment of Perianal Abscess and Fistula-in-Ano ?(Revised)显示文摘 | Mark H. Whiteford John Kilkenny Neil Hyman W. Donald Buie Jeffrey Cohen Charles Orsay Gary Dunn W. Brian Perry C. Neal Ellis Jan Rakinic Sharon Gregorcyk Paul Shellito Richard Nelson Joe J. Tjandra Graham Newstead | 2005 | Diseases of the Colon & Rectum2005，，7： | 1 |
| 7 | The non-diagnostic ultrasound in appendicitis: is a non-visualized appendix the same as a negative study?显示文摘 | Brian Cohen Jordan Bowling Peter Midulla Edward Shlasko Neil Lester Henrietta Rosenberg Aaron Lipskar | 2015 | Journal of Pediatric Surgery2015，，： | 1 |
| 8 | Practice Parameters for the Treatment of Perianal Abscess and Fistula-in-Ano ?(Revised)显示文摘 | Mark H. Whiteford M.D. John Kilkenny M.D. Neil Hyman M.D. W. Donald Buie M.D. Jeffrey Cohen M.D. Charles Orsay M.D. Gary Dunn M.D. W. Brian Perry M.D. C. Neal Ellis M.D. Jan Rakinic M.D. Sharon Gregorcyk M.D. Paul Shellito M.D. Richard Nelson M.D. Joe J. | 2005 | Diseases of the Colon & Rectum2005，，7： | 1 |
| 9 | Bueeal alveolar exostoses: prevalence, characteristics, and evidence for buttressing bone formation显示文摘 | Homing GM Cohen ME Neils TA | 2000 | J Periodontol2000，71，6： | 1 |
| 10 | Apportionment of sources of fine and coarse particles in four major Australian cities by positive matrix factorisation显示文摘 | Yiu-Chung Chan David D. Cohen Olga Hawas Eduard Stelcer Rod Simpson Lyn Denison Neil Wong Mary Hodge Eva Comino Stewart Carswell | 2007 | Atmospheric Environment2007，，2： | 1 |
| 11 | Mechanical Complications After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction (from APEX-AMI)显示文摘 | John K. French Anne S. Hellkamp Paul W. Armstrong Eric Cohen Neil S. Kleiman Christopher M. O’Connor David R. Holmes Judith S. Hochman Christopher B. Granger Kenneth W. Mahaffey | 2010 | The American Journal of Cardiology2010，，： | 1 |
| 12 | Practice Parameters for the Treatment of Perianal Abscess and Fistula-in-Ano ?(Revised)显示文摘 | Mark H. Whiteford M.D. John Kilkenny M.D. Neil Hyman M.D. W. Donald Buie M.D. Jeffrey Cohen M.D. Charles Orsay M.D. Gary Dunn M.D. W. Brian Perry M.D. C. Neal Ellis M.D. Jan Rakinic M.D. Sharon Gregorcyk M.D. Paul Shellito M.D. Richard Nelson M.D. Joe J. | 2005 | Diseases of the Colon & Rectum2005，，7： | 1 |
| 13 | 家电互联网显示文摘一个世纪前,在巴塞罗那,Antoni Gaudi先驱性的创造了一种将视觉和建筑设计无缝结合的流畅风格.他的建筑那富有表现力的曲线不仅仅是用于装饰的外表,同时它们还是承重结构的有机组成部分.不幸的是,对于建筑物内部的电子基本设施而言,类似的统一尚未实现.开关、插座和温度调节器都是事后附加在建筑结构上,这样其功能就被埋线所限制.电脑和家用电器就更是后来的侵入者了.在今天典型的住家或办公室中,各种电子设备各司其职,相互之间几乎不发生任何联系. | Neil Gershenfeld Raffi Krikorian Danny Cohen 何毓嵩 曾少立 | 2004 | 科学(中文版)2004，，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员